证券代码：002570 证券简称：贝因美 公告编号：2024-063 贝因美股份有限公司 关于董事会换届完成及选举公司董事长的公告 独立董事：俞春萍、胡军辉、黄恺 董事会中兼任公司高级管理人员的董事人数总计未超过公司董事总数的二 分之一。 公司第九届董事会任期自公司 2023 年度股东大会选举通过之日起三年。上 述人员简历详见附件。 二、各专门委员会委员 1、审计委员会（3 人）：俞春萍、胡军辉、李晓京。其中，俞春萍为主任委 员； 2、提名委员会（3 人）：胡军辉、黄恺、谢宏。其中，胡军辉为主任委员； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）2024 年 5 月 21 日召开 2023 年度 股东大会，审议通过了《关于换届选举暨提名第九届董事会非独立董事候选人的 议案》《关于换届选举暨提名第九届董事会独立董事候选人的议案》，选举产生了 公司第九届独立董事和非独立董事。同日公司召开了第九届董事会第一次会议， 审议通过了选举公司董事长、选举董事会第九届专门委员会委员等议案。公司董 事会顺利完成了换届选举，现将相关情况公 ...

贝因美股份有限公司（以下简称"公司"）2024 年 5 月 21 日召开 2023 年 度股东大会，审议通过了《关于换届选举暨提名第九届监事会非职工代表监事候 选人的议案》，选举产生了公司第九届非职工代表监事，与公司于 2024 年 4 月 26 日召开的 2024 年第一次职工代表大会选举产生的职工代表监事共同组成公司第 九届监事会。同日公司召开了第九届监事会第一次会议，审议通过了选举公司监 事会主席的议案。公司监事会顺利完成了换届选举，现将相关情况公告如下： 一、 第九届监事会组成情况 公司第九届监事会由 3 名监事组成，其中，职工代表监事 1 名，非职工代表 监事 2 名，具体成员如下： 非职工代表监事：鲍晨、赵三军 证券代码：002570 证券简称：贝因美 公告编号：2024-064 贝因美股份有限公司 关于监事会换届完成及选举公司监事会主席的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 贝因美股份有限公司 监事会 职工代表监事：汤金 公司第九届监事会任期自公司 2023 年度股东大会选举通过之日起三年。上 述人员简历详见附件。 二 ...

证券代码：002570 证券简称：贝因美 公告编号：2024-065 贝因美股份有限公司 关于聘任公司高级管理人员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 5 月 21 日召开第九届 董事会第一次会议，逐项审议通过了《关于聘任公司高级管理人员的议案》。 经公司董事长提议并经公司董事会提名委员会的审核，公司董事会同意聘任 谢宏先生为公司总经理。 经公司总经理提名并经董事会提名委员会的审核，公司董事会同意聘任金志 强先生、祝峻蕾女士、宫晓磊先生、方路遥先生为公司副总经理。经公司总经理 提名并经董事会审计委员会的审核，公司董事会同意聘任金志强先生为公司财务 总监。 上述人员任期自公司第九届董事会第一次会议审议通过之日起至第九届董 事会届满之日止。董事会中兼任公司高级管理人员以及由职工代表担任的董事人 数总计未超过公司董事总数的二分之一。 二、备查文件 1、第九届董事会第一次会议决议； 2、董事会专门委员会决议。 特此公告。 一、本次聘任情况 除上述关系外，谢宏为公司控股股东贝因美集团有限公司之控股 ...

证券代码：002570 证券简称：贝因美 公告编号：2024-059 贝因美股份有限公司 关于第二期股票期权激励计划部分股票期权注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 4 月 28 日召开第八届 董事会第三十一次会议、第八届监事会第二十次会议，审议通过了《关于第二期 股票期权激励计划未达到行权条件暨注销相关股票期权的议案》，鉴于公司 2023 年实现经审计营业收入 25.28 亿元，净利润 4,745.31 万元，两个业绩指标均未达 成第二期股票期权激励计划首次授予部分第二个行权期行权条件和预留部分第 一个行权期行权条件，所有 277 名激励对象对应可行权的股票期权 829.498 万份 均不得行权，由公司注销。 本次注销完成后，公司第二期股权激励计划剩余已授予未行权的期权数量为 8,294,980 份。具体内容详见公司于 2024 年 4 月 30 日披露于指定信息披露媒体 及巨潮资讯网（http://www.cninfo.com.cn）上的《关于第二期股票期权激励计划 未达到行 ...

证券代码：002570 证券简称：贝因美 公告编号：2024-058 贝因美股份有限公司 关于取消 2023 年度股东大会部分提案 暨 2023 年度股东大会补充通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 4 月 28 日召开第八届董 事会第三十一次会议，审议通过《关于召开 2023 年度股东大会的议案》，定于 2024 年 5 月 21 日召开 2023 年年度股东大会。详见公司 2024 年 4 月 30 日披露的《关于 召开 2023 年度股东大会的通知》（公告编号：2024-046）。 公司于 2024 年 5 月 14 日召开第八届董事会第三十二次会议，审议通过了《关 于取消 2023 年度股东大会部分提案的议案》。因大华会计师事务所（特殊普通合 伙）受到中国证券监督管理委员会江苏监管局行政处罚，基于审慎性原则，公司取 消 2023 年度股东大会中第六项提案，即《关于续聘会计师事务所的议案》。 本次 取消股东大会部分提案符合相关法律、行政法规、部门规章、规范性文件和《公司 章程》 ...

4、本次监事会会议的召集、召开和表决程序符合《公司法》等法律、法规 和《公司章程》的有关规定，合法有效。 二、监事会会议审议情况 证券代码：002570 证券简称：贝因美 公告编号：2024-057 贝因美股份有限公司 第八届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由贝因美股份有限公司（以下简称"公司"）监事会主席强 赤华先生召集和主持，会议通知于 2024 年 5 月 14 日以通讯方式发出。 2、本次监事会于 2024 年 5 月 14 日召开，采用通讯方式召开、表决。 3、本次监事会应出席监事 3 人，实际参与通讯表决的监事 3 人。公司高级 管理人员、董事会秘书列席会议。 特此公告。 贝因美股份有限公司 监事会 2024 年 5 月 15 日 1、审议通过了《关于豁免第八届监事会第二十一次会议通知时间的议案》。 根据《监事会议事规则》的规定，公司全体监事一致同意豁免本次会议通知 的期限要求。 表决结果：同意 3 票，反对 0 票，弃权 0 票。议案审议通过。 2、审议通过了《关 ...

1、本次董事会由贝因美股份有限公司（以下简称"公司"）董事长谢宏先 生召集和主持，会议通知于 2024 年 5 月 14 日以邮件方式发出。 2、本次董事会于 2024 年 5 月 14 日召开，采用通讯的方式召开、表决。 3、本次董事会应出席董事 8 人，实际参与通讯表决的董事 8 人。公司监事、 高级管理人员列席了会议。 4、本次董事会会议的召集、召开和表决程序符合《公司法》等法律、法规 和《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 证券代码：002570 证券简称：贝因美 公告编号：2024-056 贝因美股份有限公司 第八届董事会第三十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：同意 8 票，反对 0 票，弃权 0 票。议案审议通过。 1、审议通过了《关于豁免第八届董事会第三十二次会议通知时间的议案》。 根据《董事会议事规则》的规定，公司全体董事一致同意豁免本次会议通知 的期限要求。 表决结果：同意 8 票，反对 0 票，弃权 0 票。议案审议通过。 2、审议通过了《关于取消续聘会 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 1 月 15 日召开的第八 届董事会第二十九次会议审议通过了《关于回购公司股份方案的议案》，公司拟 以集中竞价交易方式回购公司 A 股股票，用于公司未来实施的股权激励计划或 员工持股计划。本次回购金额不超过人民币 30,000 万元（含），不低于人民币 15,000 万元（含），回购价格不超过 5.20 元/股（含）。根据最高回购规模、回 购价格上限测算，预计回购股份数量为 5,769.23 万股，约占公司目前总股本的 5.34%。具体内容详见公司于 2024 年 1 月 16 日披露于指定信息披露媒体及巨潮 资讯网（http://www.cninfo.com.cn）上的《关于以集中竞价交易方式回购公司股 份方案的公告》（公告编号：2024-007）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的相关规定，回购期间，上市公司应当在每个月的前三个交 易日内披露截至上月末的回购进展情况。现将公司回购股份的进展情况公告 ...

Financial Performance - The company's revenue for Q1 2024 was ¥720,455,358.38, representing a 2.28% increase compared to ¥704,386,288.42 in the same period last year[4] - Net profit attributable to shareholders increased by 80.71% to ¥22,074,986.63 from ¥12,215,392.19 year-on-year[4] - The net profit after deducting non-recurring gains and losses surged by 368.90% to ¥18,462,398.06 from ¥3,937,353.49 in the previous year[4] - The net cash flow from operating activities rose by 247.68% to ¥82,577,692.15 compared to ¥23,750,966.73 in the same period last year[4] - Basic earnings per share doubled to ¥0.02 from ¥0.01 year-on-year, with diluted earnings per share also at ¥0.02[4] - The company experienced a 60.23% increase in total profit, reaching ¥2,917,000,000.00 compared to ¥1,818,000,000.00 in the previous year[9] - Total operating revenue for Q1 2024 was CNY 720,455,358.38, an increase of 2.5% compared to CNY 704,386,288.42 in Q1 2023[27] - The net profit for the first quarter of 2024 was CNY 24,465,526.74, an increase of 77.5% compared to CNY 13,801,717.67 in the same period last year[28] - The total comprehensive income for the first quarter was CNY 32,767,894.77, compared to CNY 18,574,924.34 in the same quarter last year, marking a growth of 76.5%[29] Assets and Liabilities - Total assets decreased by 2.82% to ¥3,790,024,889.41 from ¥3,900,099,864.43 at the end of the previous year[4] - Total assets as of March 31, 2024, were CNY 3,790,024,889.41, down from CNY 3,900,099,864.43 at the beginning of the year, a decrease of 2.8%[25] - Total liabilities decreased to CNY 2,160,285,680.11 from CNY 2,258,108,718.95, a decline of 4.3%[25] Cash Flow - The company's cash flow from financing activities increased by 183.71% to ¥21,000,000.00, driven by increased bank loans and recovery of pledged time deposits[12] - Cash and cash equivalents decreased to CNY 862,833,529.39 from CNY 1,028,429,231.04, a decline of 16.1%[23] - The cash flow from operating activities showed a net increase of CNY 82,577,692.15, significantly higher than CNY 23,750,966.73 in the previous year[30] - The company incurred a net cash outflow from investing activities of CNY 172,218,066.11, compared to CNY 14,525,597.70 in the previous year, indicating increased investment activity[30] - The financing activities resulted in a net cash outflow of CNY 71,985,957.99, compared to CNY 26,579,720.89 in the same period last year, showing a higher reliance on financing[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 67,832[15] - The largest shareholder, Beingmade Group Co., Ltd., holds 16.72% of the shares, totaling 180,629,471 shares, with 179,060,971 shares pledged[15] - The company has repurchased 34,897,768 shares, accounting for 3.23% of the total share capital[16] Research and Development - Research and development expenses decreased by 43.68% to ¥262,000,000.00 from ¥465,000,000.00 year-on-year[9] - Research and development expenses for Q1 2024 were CNY 2,623,635.13, down from CNY 4,658,720.72 in Q1 2023, a decrease of 43.8%[27] Legal and Regulatory Matters - A court has frozen 53,000,000 shares held by Beingmade Group, representing 26.98% of its total shares, due to a debt enforcement application[19] - 37,013,943 shares held by Beingmade Group are frozen by the court, accounting for 19.34% of its total shares, due to a prior pledge[21] - The company is required to pay approximately $18.5 million to FNOF Treasure Train Limited as per an arbitration ruling regarding the repurchase of shares in Beingmade Health Management Corp.[21] Other Developments - The company supports the establishment of an industrial incubation fund by its subsidiary to enhance investment risk management and strategic alignment[17] - As of the announcement date, the industrial fund's registration procedures have not been completed, and the company will disclose updates on significant matters[17] - The company has completed the deregistration of 13 out of 14 subsidiaries under Beingmade Marketing Management Co., Ltd.[18]

Financial Performance - The company's operating revenue for 2023 was approximately ¥2.53 billion, representing a 0.76% increase compared to ¥2.51 billion in 2022[24]. - The net profit attributable to shareholders for 2023 was approximately ¥47.45 million, a significant turnaround from a loss of ¥176 million in 2022, marking a 126.97% improvement[24]. - The net cash flow from operating activities increased by 9.57% to approximately ¥413.55 million in 2023, up from ¥377.42 million in 2022[24]. - Basic and diluted earnings per share for 2023 were both ¥0.04, compared to a loss of ¥0.16 per share in 2022, reflecting a 125% increase[24]. - Total assets at the end of 2023 were approximately ¥3.90 billion, a 0.59% increase from ¥3.88 billion at the end of 2022[24]. - The net assets attributable to shareholders increased by 3.40% to approximately ¥1.59 billion at the end of 2023, compared to ¥1.54 billion at the end of 2022[24]. - The company achieved a total revenue of 2.528 billion yuan in 2023, representing a growth of 0.76% compared to 2022[40]. - The main business revenue reached 2.413 billion yuan, an increase of 3.07% year-on-year, with milk powder sales generating 2.337 billion yuan, up 2.66%[40]. Market and Competitive Position - The company reported a significant decline in newborn numbers, impacting the infant formula market, with intensified brand competition and high operational costs[4]. - The company is focused on expanding its market presence and increasing sales scale through resource utilization[4]. - The company is positioned to benefit from the growing demand for infant formula in lower-tier cities and towns, indicating significant future growth potential[42]. - The company has established a full industry chain layout integrating R&D, production, and sales, ensuring high-quality products for consumers[37]. - The company is leveraging data empowerment to enhance market competitiveness and operational efficiency[42]. Product Development and Quality Assurance - The company emphasizes the importance of product quality and safety, implementing advanced detection equipment and technology for quality control[7]. - The company maintains a commitment to quality assurance, ensuring food safety throughout the production process[7]. - The company continues to focus on R&D for new products, including special medical formula milk powder and various nutritional products[38]. - The implementation of new national standards for infant formula foods is expected to enhance industry concentration and improve product quality[36]. - The company has completed the registration of all infant formula products under the new national standards[42]. Cost Management and Operational Efficiency - The company plans to enhance cost management and expense control to improve competitiveness in the market[4]. - The company aims to strengthen accounts receivable collection and improve asset liquidity management to mitigate financial risks[5]. - The gross profit margin improved to 47.07%, up by 1.19 percentage points year-on-year, primarily due to reduced sales discounts and increased sales of high-margin products[54]. - The company is focused on enhancing operational efficiency by optimizing its industrial layout and reducing operational costs through standardized systems and information processes[102]. Governance and Compliance - The company’s financial report is guaranteed to be true, accurate, and complete by its management team[4]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal standards[116]. - The company maintains complete independence from its controlling shareholder in terms of business, personnel, assets, organization, and finance, ensuring autonomous operational capabilities[119]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors through designated platforms[114]. - The company revised its governance documents to enhance decision-making processes and protect investor rights, aligning with the latest legal requirements[118]. Shareholder Engagement and Management - The company held three shareholder meetings during the reporting period, ensuring equal treatment of all shareholders and facilitating their participation[110]. - The board of directors convened eight meetings, with a composition of 8 members, including 3 independent directors, complying with legal and regulatory requirements[112]. - The company reported a total of 58,000 shares held by executives at the end of the reporting period, with no changes in shareholding during the period[123]. - The company’s independent directors maintained independence and focused on protecting the interests of minority shareholders[142]. Environmental and Social Responsibility - The company has not faced any administrative penalties related to environmental issues during the reporting period[165]. - The company has implemented clean production practices and has passed certifications for clean production, energy management, and environmental management systems[165]. - The company has actively engaged in social responsibility initiatives, including the "Love Baby" project, which has been running since 1993 to support families with special needs children[166]. - The company emphasizes the importance of customer, employee, shareholder, partner, and social value in its core business philosophy[167]. Future Outlook and Strategic Initiatives - The company has provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[130]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on expanding the product line in the infant nutrition sector[130]. - Market expansion plans include entering three new provinces, which are projected to increase market share by 10%[130]. - The company is considering strategic acquisitions to enhance its supply chain efficiency and reduce costs, with a target of 200 million RMB in savings[130].